Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

No studies found 2 · 66.7%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 33.3%Moderate 0 · 0%High 0 · 0%

Adverse events (grade ≥ 3) · recurrent platinum‐resistant EOC

Chemotherapy with TKI may leads to higher any adverse events (grade ≥3) compared with chemotherapy alone (low certainty).

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
RR 1.23 [1.02, 1.49]
4 studies · 548 participants
Low

Adverse events (grade ≥ 3) · platinum‐sensitive recurrent EOC

The review found no eligible studies for this question.

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Adverse events (grade ≥ 3) · recurrent EOC

The review found no eligible studies for this question.

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found